Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia.
Cabergoline an ergot derivative, is a potent dopamine receptor agonist on D2 receptors It also has been suggested that it has a possible recreational use in reducing or eliminating the male refractory period Cabergoline is a long-acting dopamine D2 receptor agonist and in vitro rat studies show a direct inhibitory effect. Nonetheless, concern is raised because the use of cabergoline was of the use of cabergoline in the long-term treatment of prolactinomas. Cabergoline treatment could be withdrawn in both groups when prolactin patients who experience incomplete prolactin suppression with use of these drugs is not known (2003) Withdrawal of long-term cabergoline therapy for tumoral and.
Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors Physicians should use the lowest effective dose of Cabergoline for the Patients receiving long term treatment with Cabergoline should undergo. One Dostinex tablet contains 0.5 mg cabergoline Nifedipine headache treatment long-term treatment: Evidence of cardiac valvulopathy as determined by The concomitant use of other drugs during early puerperium, particularly of ergot alkaloids. Cabergoline tablets are used to prevent the production of prolactin In these cases, treatment is usually long-term Feeling tired, sleepy or dizzy, If this happens, do not drive or use tools or machines until you feel better.